fda glp-1 compounding warning october 2025 GLP-1 weight loss drugs are back in the news

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

21.73

★★★★☆4.8 (126)

The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.'

28.49

★★★★★4.9 (98)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

25.20

★★★★★5.0 (157)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

23.51

★★★★★4.7 (84)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

26.68

★★★★★4.9 (203)

Report: FDA must enforce rules on compounded GLP-1s

29.36

★★★★★5.0 (176)

GLP-1 Safety Check

21.63

★★★★★4.8 (132)